MRI developer Intermagnetics General has sued GE Medical Systems to prevent an employee from joining GE. In the lawsuit filed Oct. 18 in the Supreme State Court of Albany (NY), Intermagnetics is seeking a preliminary and permanent injunction stopping
MRI developer Intermagnetics General has sued GE Medical Systems to prevent an employee from joining GE. In the lawsuit filed Oct. 18 in the Supreme State Court of Albany (NY), Intermagnetics is seeking a preliminary and permanent injunction stopping Jinhua Huang from accepting employment or commencing work with GE or any other employer in a position in which he will be involved in the design, use, or manufacture of MRI magnet systems or components. Huang had announced that he would start work with GE on Oct. 25.
Latham, NY-based Intermagnetics says that Huang will inevitably disclose to his new employer Intermagnetics MRI systems and processes that constitute the firms trade secrets. According to court filings by Intermagnetics, Huang has been extensively involved in the engineering, design, and development of Intermagnetics MRI magnet systems, and has detailed knowledge of them. In addition, the filings say that Huang had access to and developed numerous trade secrets regarding Intermagnetics MRI systems and processes, including superconducting magnet windings, interfaces, clearances, protection systems, shimming design, computer codes, cryostat spacings, coil mechanics, cold mass suspension, and suspension techniques.
To support its request for an injunction, Intermagnetics referred to an employee confidentiality and proprietary information agreement Huang had signed with Intermagnetics in late 1991 upon joining the firm. In the agreement, Huang promised to maintain in confidence all the firms confidential information and trade secrets, according to Intermagnetics. Intermagnetics says that Huangs conduct constitutes a misappropriation of Intermagnetics trade secrets that will irreparably injure Intermagnetics business, and is also seeking an award of money damages. A GE spokesperson was unavailable for comment.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.